The use of saquinavir/ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampin.
Losso
Marcelo H
MH
Servicio de Inmunocomprometidos, Hospital General de Agudos José María Ramos Mejía, Buenos Aires, Argentina. mlosso@hivramos.org.ar
Lourtau
Leonardo D
LD
Toibaro
Javier J
JJ
Saenz
César
C
González
Claudio
C
D000328:Adult; D018791:CD4 Lymphocyte Count; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D015497:HIV-1 / Q000502:physiology; D006801:Humans; D008297:Male; D012367:RNA, Viral / Q000097:blood; D012293:Rifampin / Q000008:administration & dosage* / Q000627:therapeutic use; D019438:Ritonavir / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D019258:Saquinavir / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014376:Tuberculosis / Q000150:complications* / Q000188:drug therapy
D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D019258:Saquinavir; D019438:Ritonavir; D012293:Rifampin